Lead Product(s) : Calcipotriol,Betamethasone
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Positive results from the Phase III study with Lipidor’s drug candidate AKP02, which is based on calcipotriol alone & in combination with betamethasone, show that AKVANO® technology works well for drugs for treatment of psoriasis.
Product Name : AKP02
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2022
Lead Product(s) : Calcipotriol,Betamethasone
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Calcipotriol,Betamethasone
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AKP02 is a drug candidate for psoriasis that combines calcipotriol and betamethasone and is based on Lipidor’s patented AKVANO® technology.
Product Name : AKP02
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 22, 2021
Lead Product(s) : Calcipotriol,Betamethasone
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Calcipotriol,Beclomethasone Dipropionate
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Menarini
Deal Size : $83.1 million
Deal Type : Licensing Agreement
Details : Under the terms of this agreement, RELIFE S.r.l shall register, promote, distribute and market Lipidor's calcipotriol based drug candidates for the treatment of psoriasis in EU, Turkey, UK, Switzerland, CIS, and Balkan countries.
Product Name : AKP02
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 07, 2021
Lead Product(s) : Calcipotriol,Beclomethasone Dipropionate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Menarini
Deal Size : $83.1 million
Deal Type : Licensing Agreement
Lead Product(s) : Calcipotriol,Betamethasone
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lipidor Presents Updated Project Plan - Initiates Phase III study of AKP02 in-House
Details : Company has successfully completed Phase III study of calcipotriol spray (AKP01) against mild to moderate plaque psoriasis and is planning for a licensing project.
Product Name : AKP02
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 05, 2020
Lead Product(s) : Calcipotriol,Betamethasone
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Calcipotriol
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Both Lipidor's AKP01 and the comparator had a statistically significantly better efficacy compared to the placebo.
Product Name : AKP02
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 24, 2020
Lead Product(s) : Calcipotriol
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable